In lung cancer subtype-stratified analyses, there was weak evidence to suggest an association of genetically proxied ADRB1 inhibition with lower risk of small cell lung carcinoma (OR equivalent to 1 mm Hg lower SBP: 0.87, 95% CI 0.79 to 0.96; P = 0.008). Here, ADRB1 is linked to lung carcinoma.